Lyka Labs (BOM:500259) Retained Earnings: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500259 Lyka Labs Ltd BOM:500259
58 GF Score
Price ₹82.51
GF Value ₹129.74
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lyka Labs Retained Earnings?

Lyka Labs BOM:500259 -1.77% 58 Retained Earnings is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 58/100 and a GF Value™ of ₹129.74 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Lyka Labs's retained earnings for the quarter that ended in Jun. 2026 was ₹0 Mil.

Lyka Labs's annual retained earnings increased from Mar. 2024 (₹-1,381 Mil) to Mar. 2025 (₹-1,301 Mil) and increased from Mar. 2025 (₹-1,301 Mil) to Mar. 2026 (₹0 Mil).


Lyka Labs  (BOM:500259) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Lyka Labs Retained Earnings Historical Data

* Premium members only.

The historical data trend for Lyka Labs's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyka Labs Retained Earnings Chart

Lyka Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,224.46 -1,356.58 -1,381.47 -1,301.35 0.00

Lyka Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:500259
58GF Score
Lyka Labs Ltd BOM:500259
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyka Labs Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ₹0 Mil mean?
Lyka Labs (BOM:500259) has a Retained Earnings of ₹0 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Lyka Labs and its competitors.
Is Lyka Labs' Retained Earnings too high?
Lyka Labs' current Retained Earnings is ₹0 Mil. Overall, Lyka Labs has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Retained Earnings compare to VRTX and REGN?
Lyka Labs' Retained Earnings of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Lyka Labs and its competitors. Lyka Labs's current Retained Earnings is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹129.74, compared to a current price of ₹82.51 — trading 36.4% below its estimated fair value. The current Retained Earnings is ₹0 Mil. Lyka Labs' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Retained Earnings is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹82.51 is trading 36.4% below its estimated GF Value™ of ₹129.74. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • Retained Earnings: ₹0 Mil
  • GF Value™: ₹129.74 vs. price of ₹82.51 (36.4% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
58GF Score

Get the complete analysis for BOM:500259

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹82.51
Price
₹129.74
GF Value